Yumanity Therapeutics Announces Filing of Registration Statement on Form S-4 In Connection with Proposed Asset Sale to Janssen and Merger with Kineta
BOSTON, Aug. 29 (Korea Bizwire) — Yumanity Therapeutics, Inc. (“Yumanity”) (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced the filing of a registration statement on Form S-4 (the “Registration Statement”) with the U.S. Securities and Exchange Commission (the “SEC”). The Registration Statement contains [...]









